OncoSec Medical Inc. (NASDAQ: ONCS) Starts Presentation at The LD 500
OncoSec Medical Inc. (NASDAQ: ONCS) is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead product candidate is TAVO(TM), and the company has built a deep clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications, either as a monotherapy or in combination with leading checkpoint inhibitors. The company is currently evaluating TAVO in combination with anti-PD-1 checkpoint inhibitor KEYTRUDA(R) (pembrolizumab) in two keynote clinical trials, including a pivotal trial in patients with anti-PD-1 checkpoint-resistant metastatic melanoma and a phase 2 trial in metastatic…







